Who's the Boss? Merck Names Managerial Team As Schering Merger Looms
In a long-awaited move, Merck announced a managerial reorganization, placing several Schering-Plough executives in top management spots once the two companies finalize their proposed $41 billion merger later this year
You may also be interested in...
The specialty pharma long has been scrutinized for its decisions regarding the patent cliff and business development. Now, a new CEO will have the chance to keep the company on its current course or mirror the transformations he’s put in motion at other companies.
A consummate Merck insider, Margie McGlynn, announces her plans to retire, as the company prepares for its pending merger with Schering-Plough.
Merck and Schering argue the merger does not constitute “change of control” for Remicade and Simponi under initial J&J agreement.